Online EBSA courses 2020


Also check out the 2 webinars

2020 - online program

22 October, 11:00 – 13:00 CET

Biological risk assessment: How safe are we in our labs if we apply the risk based approach according to the new WHO Biosafety Manual?

27 October, 10:00 - 14:00 CET Blend your Biosafety Training -
How to produce and use educational technologies
3 November 10:00- 14:30 CET ISO 35001 – An introduction into the biorisk management standard
12 November, 10:00 - 15:30 CET
13 November, 10:00 - 12:00 CET

Gene therapy: main approaches and biosafety issues​


Biological Risk Assessment – How safe are we in our labs if we apply the risk based approach according to the new WHO Biosafety Manual? 
Instructor: Kathrin Summermatter
Moderator: Heather Sheeley


Managing biological risks in various environments in which hazardous biological materials are used, be it in research, diagnostic, production facilities or animal units is of utmost importance. Biosafety professionals very often play the interface between different stakeholders such as scientists, engineering, maintenance or cleaning staff.

During the COVID-19 pandemic, biosafety professionals were constantly challenged and had to apply the risk based approach again and again nearly on a daily basis. Initial risk assessments for activities in the diagnostic laboratory had to be adapted to the new conditions (e.g. shortage of safety equipment) and at the same time the safety of all laboratory staff had to be ensured.

How can we deal with the increased workload during thee COVID-19 pandemic and at the same time guarantee the safety of our employees?

In this webinar these and other questions will be addressed by using the risk based approach of the new WHO biosafety manual. 

Main Topics

  • Introduction into the key elements for risk assessment of the up-dated WHO Laboratory Biosafety Manual (LBM4)
  • Risk assessment for SARS-CoV-2 activities:
    • handling unknown samples
    • increasing number of tests

    • safety of staff

    • waste handling

CWA Reference

2 Biological and other hazards in the work area Biorisk assessment and management


22 October, 11:00 – 13:00 CET

Kathrin Summermatter

PDF icon CV KS

Heather Sheeley
PDF icon CV HS


Blend your biosafety training - how to produce and use educational technologies
Instructors: Henrik Bregnhøj, Lawrence Dickson 

This half-day course will give you an introductory experience with application of current digital educational technologies like production and use of power point-based videos, planning and execution of webinars, and the use of an Learning Management System in your teaching.

Main topics:

  • What is E-learning/Blended learning?
  • Activities done in webinars
    • Use whiteboard exercise
    • Use the chat
    • Poll
    • Breakout groups
  • Learning Management System
    • Tour around in an LMS / Blackboard
    • Use of Discussion groups
    • Use of Assessment
  • Video production​
    • Power Point with speak -> Video -> Adding subtitles in Camtasia
    • Animations in Power Point (biosafety cabinet examples) + exercise
    • Addition of quizzes to videos, incl. camera recordings
    • Screencasting -> Video editing to remove parts
    • Lecture capture 

CWA Reference

  • Training
  • Communication skills and information/knowledge systems

27 October 2020, 10:00 – 14:00 CET (lunch break 11:30 - 12:30)




ISO 35001 – An introduction into the biorisk management standard
Instructor: Toon De Kesel
Moderator: Heather Sheeley

The ISO 35001 standard on “Biorisk management for laboratories and other related organisations - is the first internationally recognized management standard to specifically address hazards associated with laboratories where biological materials are handled at all containment levels. It sets out the requirements for a management system to enable organizations to effectively identify, monitor, and control risk associated with laboratory biosafety and biosecurity.  It also provides a structured approach to managing risk associated with people, facilities and working procedures in laboratory environments.

The Biorisk management standard is a compendium of all biosafety and biosecurity issues irrespectively of actual laws or administrative provisions. It defines key requirements encompassing all relevant laws and does not focus on the application of individual pieces of legislation. Therefore, the ISO 35001 standard is deliberately general in order to accommodate national differences.

The ISO 35001 webinar aims to help you understand the fundamentals of the standard and how it can be applied to your organization. It will present the principles of biorisk management, identify the multiple components of a biorisk programme and explore ways to integrate them into the management system(s) in place or to be developed in an institution.

Main Topics

The course participants will be able to

  • Identify the fundamentals of a biorisk management system
  • Understand the scope and intend of the ISO 35001 standard
  • Understand the requirements, covering e.g. key roles and responsibilities, biorisk assessment, good microbiological techniques, healthcare, personal protection, emergency planning, biosecurity
  • Initiate or improve the implementation of the standard for their organisation

CWA Reference

The learning objectives are in line with CWA 16335:2011 on the Biosafety Professional, specifically with the CWA clause 7.2.17., “The biosafety professional shall be able to develop and support the implementation of a biorisk management programme and understand how the elements (e.g. physical, personal and informational biosecurity measures) in such a programme are interrelated so as to achieve the objectives of the programme. The biosafety professional shall be able to understand and apply the core principles and practices associated with a management system approach that incorporates continual improvement and be able to communicate them.”

3 November 10:00 - 14:30 CET

(lunch break 11:30 - 13:00)

Heather Sheeley
PDF icon CV HS


Gene therapy: main approaches and biosafety issues
Instructors: Gijsbert van Willigen, Suzanne Loret

Though the idea for gene therapy was put forward in 1972, it was not until 2003 in China and 10 years later in US, that DNA drug actually appeared on the market. Since then, at least nine gene therapies have been approved for a few cancer types, genetic disorders and viral infections and a great number of research projects and clinical trials are underway in many countries.

Target audience:

  • Laboratory professionals whose activities are involved in molecular and cell biology, including DNA recombinant technologies and cell transfection approaches
  • Health, Safety and Environment (HSE) Professionals involved in the risk assessment of molecular and cell biology activities and gene therapy clinical trials
  • Any person interested by the subject

Learning outcomes:

At the end of the course, participants should be able to:

  • get an accurate understanding of:
    • gene therapy
    • gene therapy main approaches
    • gene vector
  • perform a risk assessment of gene therapy conditions (this capacity will be tested through a group work on study cases)


  • Basics Biosafety: pathogenic organism / genetically modified organism - risk group - contained use - containment level
  • General biology: basic knowledge in cell biology and virology
  • Molecular biology: basic knowledge about cloning - expression - transfection - transduction

The training will focus on:

  • the main approaches in gene therapy (using various gene vectors), with an attention paid on the biosafety aspects in research and development laboratories, as well as on the risk for the patient
  • the viral vectors used frequently in current gene therapy project, with the aim to point out their respective benefits in term of efficacy and safety

Participants will have the opportunity to perform a team-work risk assessment on case studies corresponding to current clinical trials.

CWA 15793 Reference

  • General principles of microbiology, biochemistry and cell biology
  • General principles of molecular biology and genetic engineering
  • 2.2.10  Gene therapy activities

12 November 10:00 - 15:30 CET
(lunch break 11:30 - 14:00)

13 November 10:00-12:00 CET